ATE317021T1 - Antisense modulierung von lfa-3 - Google Patents

Antisense modulierung von lfa-3

Info

Publication number
ATE317021T1
ATE317021T1 AT99913927T AT99913927T ATE317021T1 AT E317021 T1 ATE317021 T1 AT E317021T1 AT 99913927 T AT99913927 T AT 99913927T AT 99913927 T AT99913927 T AT 99913927T AT E317021 T1 ATE317021 T1 AT E317021T1
Authority
AT
Austria
Prior art keywords
lfa
antisense modulation
treatment
modulation
diagnosis
Prior art date
Application number
AT99913927T
Other languages
English (en)
Inventor
C Frank Bennett
Thomas P Condon
Shin Cheng Flournoy
Jordan S Pober
Weillie Ma
Original Assignee
Isis Pharmaceuticals Inc
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc, Univ Yale filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE317021T1 publication Critical patent/ATE317021T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
AT99913927T 1998-03-20 1999-03-17 Antisense modulierung von lfa-3 ATE317021T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/045,106 US6001651A (en) 1998-03-20 1998-03-20 Antisense modulation of LFA-3

Publications (1)

Publication Number Publication Date
ATE317021T1 true ATE317021T1 (de) 2006-02-15

Family

ID=21936028

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99913927T ATE317021T1 (de) 1998-03-20 1999-03-17 Antisense modulierung von lfa-3

Country Status (7)

Country Link
US (1) US6001651A (de)
EP (1) EP1064402B1 (de)
JP (1) JP3590585B2 (de)
AT (1) ATE317021T1 (de)
AU (1) AU3189199A (de)
DE (1) DE69929683D1 (de)
WO (1) WO1999047707A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503754B1 (en) * 2000-09-07 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of BH3 interacting domain death agonist expression
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
RU2293573C2 (ru) * 2000-06-08 2007-02-20 Интерселл Аг Иммуностимулирующие олигодезоксинуклеотиды
US20110171296A1 (en) * 2000-10-30 2011-07-14 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
US7105657B2 (en) * 2002-11-08 2006-09-12 Board Of Regents Of The University Of Nebraska Compositions and methods for inhibiting pancreatic cancer metastasis
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
DE4008354A1 (de) * 1990-03-15 1991-09-19 Basf Ag Neues protein, seine herstellung und verwendung
WO1992004463A1 (de) * 1990-09-04 1992-03-19 Basf Aktiengesellschaft Cd58 spezifischer monoklonaler antikörper und dessen verwendung
AU660981B2 (en) * 1991-03-12 1995-07-13 Astellas Us Llc CD2-binding domain of lymphocyte function associated antigen 3
WO1992016563A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Monoclonal antibodies recognizing lymphocyte function associated antigen-3
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
ATE210454T1 (de) * 1991-10-07 2001-12-15 Biogen Inc Verfahren zur verbesserung der toleranz für allotransplantaten und xenotransplantaten durch verabreichung eines lfa-3- oder cd2- bindungsproteins
JPH07502496A (ja) * 1991-10-07 1995-03-16 バイオゲン　インコーポレイテッド Ｃｄ２／ｌｆａ−３相互作用の阻害剤を用いる抗原提示細胞による皮膚障害の予防または治療の方法
CZ283488B6 (cs) * 1992-08-20 1998-04-15 Schering Corporation Farmaceutický prostředek obsahující IL-4 a/nebo IL-10 nebo protilátky proti IL-4 a IL-10, způsob jeho výroby a jeho použití
SE9302738L (sv) * 1993-08-25 1995-02-26 Cito Trading Co Anordning för kraftöverföring mellan räl för spårbundet fordon och fundament
EP0773993A4 (de) * 1994-08-19 2000-07-05 Gen Hospital Corp Gentechnisch veränderte schweine-zellen
WO1996033217A1 (fr) * 1995-04-19 1996-10-24 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Proteine d'adhesion de cellules, agent immunosuppresseur contenant cette proteine et agent immunosuppresseur renfermant des cellules ainsi induites
JP4513988B2 (ja) * 2006-01-25 2010-07-28 日本電気株式会社 起動信号検出回路

Also Published As

Publication number Publication date
AU3189199A (en) 1999-10-11
WO1999047707A1 (en) 1999-09-23
EP1064402A4 (de) 2003-06-11
EP1064402A1 (de) 2001-01-03
EP1064402B1 (de) 2006-02-01
JP3590585B2 (ja) 2004-11-17
JP2002506658A (ja) 2002-03-05
US6001651A (en) 1999-12-14
DE69929683D1 (de) 2006-04-13

Similar Documents

Publication Publication Date Title
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
EP1064403A4 (de) Antisense modulation von pecam-1
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
NL300273I1 (nl) DNA dat humaan papillomavirus type 18 codeert.
DE3882775T2 (de) Zusammensetzung zur Behandlung von parodontaler Krankheit.
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
AU6353294A (en) Analogs for specific oligosaccharide-protein interactions and uses therefor
ATE317021T1 (de) Antisense modulierung von lfa-3
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
HUT77029A (hu) A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk
MX9806041A (es) Proteina purificada sr-p70.
SE9602822D0 (sv) New receptor
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
DE68908445T2 (de) Mittel zur Behandlung von Lebererkrankungen.
IT8721945A0 (it) Procedimento per la profumazione di libri, dispositivo per l'attuazione di detto procedimento
SE9604439D0 (sv) New receptor
FI973762A0 (fi) Ny gen
DE59611353D1 (de) Transketolase-verwandtes protein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties